×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
EVGN – evogene ltd. - ordinary shares (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
EVGN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/4
10:00 pm
evgn
Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer
Medium
Report
Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer
2/4
08:19 am
evgn
Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer [Yahoo! Finance]
High
Report
Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer [Yahoo! Finance]
2/4
08:00 am
evgn
Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer
Low
Report
Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer
1/7
07:13 am
evgn
Evogene and Unravel Biosciences Announce Collaboration to Develop a First-in-Class Therapy to Reverse Neurological Damage in Demyelinating Disorders [Yahoo! Finance]
Medium
Report
Evogene and Unravel Biosciences Announce Collaboration to Develop a First-in-Class Therapy to Reverse Neurological Damage in Demyelinating Disorders [Yahoo! Finance]
1/7
07:00 am
evgn
Evogene and Unravel Biosciences Announce Collaboration to Develop a First-in-Class Therapy to Reverse Neurological Damage in Demyelinating Disorders
Medium
Report
Evogene and Unravel Biosciences Announce Collaboration to Develop a First-in-Class Therapy to Reverse Neurological Damage in Demyelinating Disorders
12/30
08:23 am
evgn
Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development [Yahoo! Finance]
Low
Report
Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development [Yahoo! Finance]
12/30
07:00 am
evgn
Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development
Medium
Report
Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development
11/20
07:00 am
evgn
Evogene Reports Third Quarter 2025 Financial Results
Medium
Report
Evogene Reports Third Quarter 2025 Financial Results
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/4
08:00 am
evgn
Form 6-K Evogene Ltd. For: Feb 04
Low
Report
Form 6-K Evogene Ltd. For: Feb 04
1/15
04:00 pm
evgn
Form 6-K Evogene Ltd. For: Jan 15
Neutral
Report
Form 6-K Evogene Ltd. For: Jan 15
12/30
07:00 am
evgn
Form 6-K Evogene Ltd. For: Dec 30
Medium
Report
Form 6-K Evogene Ltd. For: Dec 30
11/20
07:00 am
evgn
Form 6-K Evogene Ltd. For: Nov 20
Medium
Report
Form 6-K Evogene Ltd. For: Nov 20
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/25
Form 6-K Evogene Ltd. For: Mar 25
17.4%
4/27 Form 20-F Evogene Ltd. For: Dec 31 11.3%
5/7 Evogene Financial Results for the First Quarter of 2019 3.9%
8/9 Evogene (EVGN) Investor Presentation - Slideshow [Seeking Alpha] 3.5%
5/21 Evofuel to Participate in the 2019 International Castor Oil Association - ICOA Conference 2.9%
7/10 Lavie Bio Announces Positive 2nd Year Field Results in Its Bio-stimulant Program for Wheat 2.6%
2/12 Evogene Financial Results for the Fourth Quarter and Full Year of 2019 Earnings Announcement Schedule 2.1%
7/15 Evogene to Present at Jefferies 2019 Industrials Conference 2.0%
5/14 Form 6-K Evogene Ltd. For: May 14 1.7%
1/28 Form 6-K Evogene Ltd. For: Jan 28 1.3%
4/27 Form 20-F Evogene Ltd. For: Dec 31 11.3%
5/7 Evogene Financial Results for the First Quarter of 2019 3.9%
8/9 Evogene (EVGN) Investor Presentation - Slideshow [Seeking Alpha] 3.5%
5/21 Evofuel to Participate in the 2019 International Castor Oil Association - ICOA Conference 2.9%
7/10 Lavie Bio Announces Positive 2nd Year Field Results in Its Bio-stimulant Program for Wheat 2.6%
2/12 Evogene Financial Results for the Fourth Quarter and Full Year of 2019 Earnings Announcement Schedule 2.1%
7/15 Evogene to Present at Jefferies 2019 Industrials Conference 2.0%
5/14 Form 6-K Evogene Ltd. For: May 14 1.7%
1/28 Form 6-K Evogene Ltd. For: Jan 28 1.3%
TOP News Decliners
1/13
Biomica Enters New Agreement with Biose Industrie for Scale-up and GMP Production of Drug Candidates BMC121 & BMC127 for its Immuno-Oncology Program
-6.6%
7/31 Q2/2019 6/30/2019 EPS -0.160 ZacksConsensus N/A ActVsEst N/A - N/A -5.4%
3/4 Q4/2019 12/31/2019 EPS -0.240 ZacksConsensus N/A ActVsEst N/A - N/A -5.2%
7/16 Evogene Amends its Collaboration Agreement With Bayer to Include Genome Editing Targets -5.1%
2/11 Form SC 13G/A Evogene Ltd. Filed by: UBS Group AG -4.4%
2/7 Form SC 13G/A Evogene Ltd. Filed by: Senvest Management, LLC -3.6%
8/7 Form 6-K Evogene Ltd. For: Aug 07 -3.2%
7/11 Evogene Financial Results for the Second Quarter of 2019 Earnings Announcement Schedule -2.6%
11/18 Lavie Bio Announces Advancement in Its Product Development Pipeline for Wheat Bio-stimulants -2.3%
5/28 Q1/2019 3/31/2019 EPS -0.150 ZacksConsensus N/A ActVsEst N/A - N/A -1.7%
7/31 Q2/2019 6/30/2019 EPS -0.160 ZacksConsensus N/A ActVsEst N/A - N/A -5.4%
3/4 Q4/2019 12/31/2019 EPS -0.240 ZacksConsensus N/A ActVsEst N/A - N/A -5.2%
7/16 Evogene Amends its Collaboration Agreement With Bayer to Include Genome Editing Targets -5.1%
2/11 Form SC 13G/A Evogene Ltd. Filed by: UBS Group AG -4.4%
2/7 Form SC 13G/A Evogene Ltd. Filed by: Senvest Management, LLC -3.6%
8/7 Form 6-K Evogene Ltd. For: Aug 07 -3.2%
7/11 Evogene Financial Results for the Second Quarter of 2019 Earnings Announcement Schedule -2.6%
11/18 Lavie Bio Announces Advancement in Its Product Development Pipeline for Wheat Bio-stimulants -2.3%
5/28 Q1/2019 3/31/2019 EPS -0.150 ZacksConsensus N/A ActVsEst N/A - N/A -1.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: